TB Alliance Welcomes Global Drug Facility’s Listing of Pretomanid

Written By Jess Wiggs
TB Alliance-GDF Statement_photo.jpg

The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines. The “global access price” of US $364 for a six-month treatment course will be available to 150 countries representing the vast majority of the global TB burden.

"We applaud the GDF’s rapid response and view this listing as a significant milestone on the path to ensuring access for those in urgent need," said Mel Spigelman, President and CEO, TB Alliance, which developed the new treatment option.

According to GDF, pretomanid is already included in the GDF product catalogue and supply is expected to start once the World Health Organization makes a recommendation on pretomanid and BPaL.

Learn more about this announcement at Stop TB Partnership’s website

Jess Wiggs
Previous

TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China
Next

TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB